ADORA2A and Parkinson disease: For example, inhibition of the striatopallidal motor pathway with selective A2AR antagonists like tozadenant (4-hydroxy-N-(4-methoxy-7-morpholin-4-yl-1,3-benzo[d]thiazol-2-yl)-4-methylpiperidine-1-carboxamide) has been pursued as a non-dopaminergic treatment option for Parkinson’s disease (PD) [11,12].